- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
DAX1 (NR0B1) Antibody (C-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP2708b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
DAX1 (NR0B1) Antibody (C-term) - Product info | |
| Application | WB
|
| Primary Accession | P51843 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 51718 Da |
DAX1 (NR0B1) Antibody (C-term) - Additional info | |
| Gene ID 190 | |
| Other Names NR0B1; AHC; DAX1; Nuclear receptor subfamily 0 group B member 1; DSS-AHC critical region on the X chromosome protein 1; Nuclear receptor DAX-1 | |
| Target/Specificity This DAX1 (NR0B1) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 311~341 amino acids from the C-terminal region of human NROB1. | |
| Dilution WB~~1:%0~100WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions DAX1 (NR0B1) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
DAX1 (NR0B1) Antibody (C-term) - Protein Information | |
| Name NR0B1 | |
| Synonyms AHC, DAX1 | |
| Function Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency (By similarity) | |
| Cellular Location Nucleus. Cytoplasm. Note=Shuttles between the cytoplasm and nucleus. Homodimers exits in the cytoplasm and in the nucleus | |
DAX1 (NR0B1) Antibody (C-term) - Related products
AP2708a: DAX1 (NR0B1) Antibody (N-term)
AP2708b: DAX1 (NR0B1) Antibody (C-term)
RI13660: NR0B1 predesign siRNA
BP2708a: NROB1 Antibody (N-term) Blocking Peptide
DAX1 (NR0B1) Antibody (C-term) - Application data
-
Western blot analysis of NROB1 (arrow) using rabbit polyclonal NROB1 Antibody (Human C-term) (Cat.#AP2708b). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the NROB1 gene (Lane 2) (Origene Technologies).
DAX1 (NR0B1) Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
NROB1contains a DNA-binding domain and acts as a dominant-negative regulator of transcription which is mediated by the retinoic acid receptor. This protein also functions as an anti-testis gene by acting antagonistically to Sry. Mutations in the NROB1 gene result in both X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism.
REFERENCES
Calliari,L.E., Genet. Mol. Res. 6 (2), 177-183 (2007) Kinsey,M., Mol. Cancer Res. 4 (11), 851-859 (2006)